Viatris Inc. Common Stock
Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.
VTRS Overview
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$10.6500 |
Previous Close Volume |
4880000 |
Latest News
- Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology 18 Dec 2024 07:34:20
-
Viatris Reports Third Quarter Financial Results for 2024
07 Nov 2024 07:20:23
https://newsroom.viatris.com/2024-11-07-Viatris-Reports-Third-Quarter-Financial-Results-for-2024
-
Viatris Announces Third Quarter 2024 Dividend
05 Nov 2024 07:05:10
https://newsroom.viatris.com/2024-11-05-Viatris-Announces-Third-Quarter-2024-Dividend
- Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference 29 Oct 2024 09:04:59
- Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe 16 Oct 2024 16:38:36
- Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD) 09 Oct 2024 07:08:32
-
Viatris Announces the Pricing Terms of Maximum Tender Offer
18 Sep 2024 11:35:11
https://newsroom.viatris.com/2024-09-18-Viatris-Announces-the-Pricing-Terms-of-Maximum-Tender-Offer
- Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024 16 Sep 2024 16:35:26
- Viatris Announces Expiration and Results of Any and All Cash Tender Offers 10 Sep 2024 19:05:09
- Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers 10 Sep 2024 11:50:18
- Viatris Announces Cash Tender Offers for Certain Outstanding Notes 04 Sep 2024 03:35:30
- Viatris Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress 23 Aug 2024 07:04:57
-
Viatris Reports Second Quarter Financial Results for 2024
08 Aug 2024 07:09:20
https://newsroom.viatris.com/2024-08-08-Viatris-Reports-Second-Quarter-Financial-Results-for-2024
-
Viatris Announces Second Quarter 2024 Dividend
06 Aug 2024 07:09:42
https://newsroom.viatris.com/2024-08-06-Viatris-Announces-Second-Quarter-2024-Dividend
- Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture 03 Jul 2024 08:39:54
- U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation 02 Jul 2024 07:40:28
- Viatris Statement Regarding European Commission’s Approval for Proposed Divestiture of its Over-the-Counter Business to Cooper Consumer Health 26 Jun 2024 11:39:25
- Viatris to Report Second Quarter 2024 Financial Results on August 8, 2024 07 Jun 2024 07:09:54
- Viatris to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference 04 Jun 2024 07:10:06
- Viatris Statement on the Close of the Active Pharmaceutical Ingredients Business Divestiture 03 Jun 2024 09:40:24
- Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors 03 Jun 2024 07:10:20
- Viatris to Participate in the Jeffries Global Healthcare Conference 31 May 2024 07:09:52
- Viatris Publishes 2023 Sustainability Report: Building Sustainable Access at Scale 21 May 2024 07:24:48
- Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges 09 May 2024 07:25:02
- Viatris to Participate in the BofA Securities 2024 Health Care Conference 02 May 2024 17:25:15
- Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health 01 May 2024 07:25:15
- Viatris to Report First Quarter 2024 Financial Results on May 9, 2024 16 Apr 2024 16:30:54
-
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
15 Apr 2024 08:25:32
https://newsroom.viatris.com/2024-04-15-Viatris-Appoints-Corinne-Le-Goff-as-Chief-Commercial-Officer
- Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States 01 Apr 2024 07:26:00
- Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline 27 Mar 2024 07:25:39
- Viatris Statement Regarding the Closing of Global Research and Development Collaboration with Idorsia 18 Mar 2024 02:25:46
- Viatris Statement Regarding the Transaction with Insud Pharma 12 Mar 2024 10:25:41
- Viatris and Mapi Pharma Statement Regarding New Drug Application for GA Depot 11 Mar 2024 07:25:38
- Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance 28 Feb 2024 06:41:53
- Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration 28 Feb 2024 01:11:00
- Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results 05 Feb 2024 07:10:57